Compare Stocks: ZLAB, IONS, PRAX, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$62.43 -1.5%	$63.31	$42.13 ▼ $86.74	$10.53B	0.41	2.37 million shs	1.63 million shs
PRAX Praxis Precision Medicines	$367.85 -2.5%	$333.78	$37.19 ▼ $392.70	$10.54B	2.78	447,592 shs	242,858 shs
SMMT Summit Therapeutics	$14.33 +0.7%	$14.12	$12.07 ▼ $29.23	$11.35B	-1.23	5.37 million shs	4.84 million shs
ZLAB Zai Lab	$26.82 +3.0%	$21.14	$15.96 ▼ $34.72	$2.96B	0.78	1.25 million shs	597,324 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-0.33%	+4.21%	+13.22%	-18.07%	+50.25%
PRAX Praxis Precision Medicines	+2.54%	-2.28%	+19.50%	+7.02%	+687.83%
SMMT Summit Therapeutics	+6.51%	+8.54%	+8.63%	-18.27%	-47.26%
ZLAB Zai Lab	-0.53%	-2.58%	+39.65%	+40.85%	-24.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$62.43 -1.5%	$63.31	$42.13 ▼ $86.74	$10.53B	0.41	2.37 million shs	1.63 million shs
PRAX Praxis Precision Medicines	$367.85 -2.5%	$333.78	$37.19 ▼ $392.70	$10.54B	2.78	447,592 shs	242,858 shs
SMMT Summit Therapeutics	$14.33 +0.7%	$14.12	$12.07 ▼ $29.23	$11.35B	-1.23	5.37 million shs	4.84 million shs
ZLAB Zai Lab	$26.82 +3.0%	$21.14	$15.96 ▼ $34.72	$2.96B	0.78	1.25 million shs	597,324 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-0.33%	+4.21%	+13.22%	-18.07%	+50.25%
PRAX Praxis Precision Medicines	+2.54%	-2.28%	+19.50%	+7.02%	+687.83%
SMMT Summit Therapeutics	+6.51%	+8.54%	+8.63%	-18.27%	-47.26%
ZLAB Zai Lab	-0.53%	-2.58%	+39.65%	+40.85%	-24.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$94.15	50.81% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$585.95	59.29% Upside
SMMT Summit Therapeutics	2.44	Hold	$24.07	67.99% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$37.25	38.89% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, IONS, PRAX, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/25/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$11.90
8/25/2026	SMMT Summit Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$9.80 ➝ $11.90
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/19/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform ➝ Market Perform	$60.00
8/18/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/18/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/12/2026	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$12.00 ➝ $13.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$944M	10.99	N/A	N/A	$2.65 per share	23.56
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	$48.03 per share	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A
ZLAB Zai Lab	$460.16M	6.63	N/A	N/A	$5.34 per share	5.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/4/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)
ZLAB Zai Lab	-$175.54M	-$1.71	N/A	N/A	N/A	-41.86%	-27.43%	-16.72%	11/5/2026 (Estimated)

Latest ZLAB, IONS, PRAX, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	-$0.46	+$0.2194	-$0.50	$103.87 million	$106.31 million
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.08	-$0.69	+$0.39	-$0.69	$189.10 million	$267.95 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A
6/30/2026	Q2 2026	ZLAB Zai Lab	N/A	-$0.50	N/A	-$0.50	N/A	$106.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
PRAX Praxis Precision Medicines	N/A	15.73	15.73
SMMT Summit Therapeutics	N/A	6.96	6.96
ZLAB Zai Lab	N/A	2.13	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
PRAX Praxis Precision Medicines	67.84%
SMMT Summit Therapeutics	4.61%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	1.81%
PRAX Praxis Precision Medicines	3.00%
SMMT Summit Therapeutics	83.50%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

ZLAB, IONS, PRAX, and SMMT Headlines

Recent News About These Companies

Z.ai shares surge 8% after releasing new AI model running only on Chinese chips

August 26 at 12:00 AM | cnbc.com

Zai Lab: Revenue Growth And Zoci's Upside Optionality

August 19, 2026 | seekingalpha.com

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) CFO Sells 619 Shares

August 14, 2026 | insidertrades.com

Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock

August 13, 2026 | marketbeat.com

William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock

August 13, 2026 | marketbeat.com

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?

August 12, 2026 | marketbeat.com

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

August 10, 2026 | finance.yahoo.com

Zai Lab Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS

August 6, 2026 | marketbeat.com

Zai Lab Limited (ZLAB) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 6, 2026 | zacks.com

Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings

August 6, 2026 | marketbeat.com

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 6, 2026 | businesswire.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of “Moderate Buy” from Analysts

August 4, 2026 | defenseworld.netD

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts

August 4, 2026 | marketbeat.com

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 3, 2026 | finance.yahoo.com

Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZLAB, IONS, PRAX, and SMMT Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$62.43 -0.93 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$62.26 -0.17 (-0.28%)

As of 07:56 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Praxis Precision Medicines NASDAQ:PRAX

$367.85 -9.52 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$367.51 -0.34 (-0.09%)

As of 07:37 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$14.33 +0.10 (+0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$14.26 -0.07 (-0.46%)

As of 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Zai Lab NASDAQ:ZLAB

$26.82 +0.79 (+3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$26.82 0.00 (0.00%)

As of 07:30 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLAB, IONS, PRAX, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLAB, IONS, PRAX, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLAB, IONS, PRAX, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZLAB, IONS, PRAX, and SMMT Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Praxis Precision Medicines NASDAQ:PRAX

Summit Therapeutics NASDAQ:SMMT

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZLAB, IONS, PRAX, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZLAB, IONS, PRAX, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZLAB, IONS, PRAX, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZLAB, IONS, PRAX, and SMMT Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Praxis Precision Medicines NASDAQ:PRAX

Summit Therapeutics NASDAQ:SMMT

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools